pillbase.ru

JAKAFI XR

Active substance: ruxolitinib

TABLET, EXTENDED RELEASE · RUXOLITINIB 44 mg/1

United StatesActive

Marketing holder: Incyte Corporation

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
EU 3
  • Jakavi
    ruxolitinib phosphate
    EMEA/H/C/002464
    Novartis Europharm Limited
  • Opzelura
    ruxolitinib
    EMEA/H/C/005843
    Incyte Biosciences Distribution B.V.
  • Ruxolitinib Zentiva
    ruxolitinib hemifumarate
    EMEA/H/C/006791
    Zentiva k.s.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-6cfd-72ee-a498-1d2e3837c147,01a1208c-6cff-7121-8be2-16e85d7d72c3,01a1208c-6d00-7f2b-8d8b-5330b1dc625a,01a1208d-32f2-7c32-9ca0-d88662df4010,01a1208d-32f6-713b-824b-41e4e8d5968b;count=11 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
50881-044
Registration status
Active
Dispensing
Prescription only
Route
ORAL
Sources
  • product · openFDA NDC · 50881-044 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 50881-044 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 50881-044 · Verified 2026-10-09 · open in source